IVIG Privigen denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Privigen as Experimental — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) is an FDA-approved biologic with multiple labeled indications, including primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and chronic immune thrombocytopenic purpura (ITP). An "experimental" or "investigational" denial from UnitedHealthcare most commonly occurs when Privigen is prescribed for an off-label indication — meaning a use not explicitly listed on the FDA label — and UHC's clinical policy has not yet recognized that use as medically accepted. It can also occur in error when the plan incorrectly codes an on-label use as investigational.

## Why This Denial Is Appealable

For on-label uses, an experimental denial is a clear error and should be overturned with basic documentation. For off-label uses, the standard is whether the use is supported by medical evidence and recognized in authoritative compendia or clinical practice guidelines — not whether the FDA specifically approved that indication. Federal law (specifically for oncology) and many state laws require coverage of off-label uses that meet an evidence-based standard. Even outside oncology, UHC's full-and-fair review obligation requires genuine evaluation of the clinical literature.

## Federal Appeal Framework

• ERISA §503 (employer plans): Entitles you to the specific criteria UHC used and a meaningful internal review.
• ACA §2719 / State external review: Experimental/investigational denials are specifically eligible for external review under federal rules. An independent reviewer will assess whether the use is consistent with medical evidence and accepted clinical practice. Act within approximately four months of your denial notice.
• Expedited review: Request it if your condition is acute or if delaying treatment creates significant clinical risk.

## Your Appeal Process

1. Obtain the denial letter and UHC's Privigen coverage policy identifying the specific experimental/investigational basis. 2. Confirm whether your use is on-label or off-label — check the FDA-approved prescribing information. 3. If on-label, file a Level 1 appeal with the prescribing information and your diagnosis documentation; the denial should reverse quickly. 4. If off-label, build a literature-supported appeal and proceed through internal and external review.

## Documentation to Gather

• Diagnosis confirmation: Specialist notes, diagnostic workup, and lab or imaging records establishing your condition.
• FDA prescribing information: The current Privigen label listing approved indications — essential for on-label appeals.
• Clinical literature (off-label): Published peer-reviewed evidence or recognized guideline organization support for your specific use (reference the relevant society generically, e.g., applicable neurology or immunology society guidelines).
• Medical-necessity letter: Your prescriber's explanation of the evidence base and why Privigen is appropriate for your case, referencing authoritative sources without fabricating statistics.
• Compendia references (if applicable): For off-label oncology-adjacent or rare-disease uses, reference relevant recognized drug compendia support.

## Criteria-Mapping Strategy

Obtain UHC's published clinical policy for IVIG/Privigen and identify every criterion used to classify the use as experimental. Map each criterion to your chart evidence and the applicable clinical guidance. If UHC's policy predates recent evidence or guideline updates, your prescriber's letter should note that the policy may not reflect current medical consensus.